Results 161 to 170 of about 4,929,681 (330)
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir +12 more
wiley +1 more source
Sensor-Driven Human-Robot Synergy: A Systems Engineering Approach. [PDF]
Tsolakis N, Gasteratos A.
europepmc +1 more source
Engineering a colorimetric yeast-based assay to detect small molecules in the gastrointestinal system [PDF]
Louis Dacquay +4 more
openalex +1 more source
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He +8 more
wiley +1 more source
Complex Engineering Systems and Systems Engineering [PDF]
openaire +1 more source
Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia +9 more
wiley +1 more source
The Inventory Cost of an Engineering Project Supply Chain Based on System Dynamics [PDF]
LU Qiu-qin, Pengfei Chen
openalex +1 more source
Functionalizing cell-free systems with CRISPR-associated proteins: Application to RNA-based circuit engineering [PDF]
François-Xavier Lehr +5 more
openalex +1 more source
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source

